Browsing Tag
AstraZeneca PLC
15 posts
AstraZeneca has 180 pipeline projects. Why is it cutting costs while investing more in R&D?
AstraZeneca is launching a three-year programme targeting about $1.5 billion of annual savings, with some roles expected to disappear even as the pharmaceutical group reinvests most of the benefit into a rapidly expanding pipeline.
Avacta wins pre|CISION R&D award, but AVA6103’s H1 2027 efficacy test matters more
Avacta Group plc has moved AVA6103 into its fourth Phase 1 dose level after early human data supported the intended controlled-release mechanism of its pre|CISION platform. The next valuation test is shifting from pharmacokinetic validation to whether higher payload exposure produces meaningful antitumour activity.
Guardant360 enters a new breast cancer workflow built on testing every three months
Guardant Health has secured FDA approval for Guardant360 CDx as the companion diagnostic for AstraZeneca’s Etcamah, introducing repeated liquid-biopsy testing during first-line metastatic breast cancer therapy.
FDA advisers voted 6-3 against AstraZeneca’s breast cancer strategy. The drug was just approved anyway
The U.S. Food and Drug Administration has granted accelerated approval to AstraZeneca’s Etcamah after a Phase III trial showed a 56% reduction in progression or death, creating the first U.S. cancer treatment strategy triggered by a resistance mutation found in blood before imaging shows disease progression.
AstraZeneca (AZN) shares fall as Wainua Phase III trial miss dents ATTR-CM growth hopes
Read how AstraZeneca’s Wainua trial miss reshapes AZN stock sentiment, ATTR-CM competition and its 2030 growth story after July 9.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
Could Datroway become AstraZeneca and Daiichi Sankyo’s next major oncology franchise after Enhertu?
atroway has received a positive European regulatory recommendation for first-line treatment of metastatic triple-negative breast cancer in patients unable to receive immunotherapy. The decision moves AstraZeneca PLC and Daiichi Sankyo Company, Limited closer to opening a commercially important market while increasing the strategic value of their antibody drug conjugate partnership.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?
Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?